What Researchers Did
This study described the diagnosis and management of a 30-year-old special forces officer who developed high-altitude pulmonary edema (HAPE) during training in Nepal.
What They Found
The patient, who had ascended 3,000m in three days and was taking acetazolamide, developed classic HAPE symptoms at an elevation of 13,550 feet (4,130m). Researchers analyzed the treatment options used and not used, including a portable hyperbaric chamber, in a remote, resource-limited environment.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
As a single case report, the findings from this study may not be generalizable to all individuals experiencing high-altitude pulmonary edema.